Clinical trials: Dermatitis, open to volunteers
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Allergic Contact Dermatitis, Osteoarthritis, Hip
Rate of Allergic Contact Dermatitis and Cosmetic Outcomes
The patients from the Department of Orthopaedics Center for Joint Replacement will be asked to participate in the study. These patients will be randomized to one of three wound closure products, Sylke adhesive dressing, Exofin…
- Conditions
- Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT06957444
- Testing
- Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- West Virginia University
Atopic Dermatitis
Adjunctive Oral Iron Supplementation in Atopic Dermatitis
The present randomized controlled trial aims to evaluate the effect of adjunctive oral iron supplementation on disease severity and quality of life in adolescents with mild to moderate atopic dermatitis.
- Trial name
- NCT07613190
- Testing
- Oral iron
- Volunteers
- 124 people
- Sponsor
- Cairo University
Asthma, Respiratory Tract Infections
VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma
The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that…
- Conditions
- Asthma, Respiratory Tract Infections, Gastrointestinal Infection, Croup
- Trial name
- VICTORY (NCT06570889)
- Testing
- Cholecalciferol D3, Olive oil
- Where
- Denmark
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Professor Klaus Bønnelykke
Immune-related Dermatitis
An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors
To assess the safety and efficacy of QD 0.3% topical roflumilast foam in patients with cutaneous adverse events due to checkpoint inhibitors over 16 weeks, with or without previous treatment.
- Trial name
- NCT07639840
- Testing
- Roflumilast 0.3% topical foam
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Hand-foot Syndrome, Hand-foot Skin Reaction
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering.
- Trial name
- DermLight (NCT04979078)
- Testing
- Photobiomodulation therapy (PBMT)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jessa Hospital
Atopic Dermatitis
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
'Mind and Skin': A prospective cohort study evaluating the impact of inflammation, itch and sleep disturbance on the brain, mental health and cognition, in patients with severe atopy.
- Trial name
- NCT05790330
- Testing
- Methotrexate, Dupilumab
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- King's College London
Atopic Dermatitis
A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks
This randomized controlled trial compares the effectiveness and safety of topical tacrolimus 0.03% and crisaborole 2% in patients with mild to moderate atopic dermatitis over 8 weeks.
- Trial name
- eczema (NCT07519174)
- Testing
- Tacrolimus, Crisaborole 2% Top Oint
- Where
- Pakistan
- Volunteers
- 72 people
- Sponsor
- Foundation University Islamabad
Atopic Dermatitis
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT06775860
- Testing
- ICP-332 Tablets
- Where
- 62 sites in China
- Volunteers
- 552 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Stasis Dermatitis
Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis
This study tests two types of lasers (ND YAG 1064 short and ultra-short pulses) to treat hyperchromic skin lesions secondary to venous hypertension (stasis dermatitis)
- Trial name
- SUPERSTAR (NCT06980961)
- Testing
- short-pulse ND: YAG 1064 laser, ultra-short-pulse ND: YAG 1064 laser, cold cream
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Science Valley Research Institute
Lichen Simplex Chronicus
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07013097
- Testing
- PG-033
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region
Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
Hypothesis: Treatment with tralokinumab in patients with moderate-to-severe AD involving the genital region is expected to lead to significant improvements in PROs and clinical disease severity.
- Trial name
- AD Genital (NCT07444801)
- Testing
- tralokinumab
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Schleswig-Holstein
Celiac Disease, Dermatitis Herpetiformis
Background of Different Phenotypes of Coeliac Disease
The main purpose of this study is to investigate genetic, serological, immunological and microbiata diversities between different coeliac disease phenotypes and to discover applicable prognostic markers for specific phenotypes.
- Trial name
- NCT05597904
- Testing
- Genetic predisposition
- Where
- Finland
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Atopic Dermatitis
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
- Trial name
- NCT04455906
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Boston Children's Hospital
Radiation Dermatitis, Skin Microbiome
The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
The breast cancer patients who received radiotherapy after mastectomy and breast reconstruction will be enrolled. The skin microbiome before radiotherapy and its changes after radiotherapy will be analyzed systematically to find…
- Conditions
- Radiation Dermatitis, Skin Microbiome, Breast Cancer, Reconstructive Surgery
- Trial name
- NCT05032768
- Testing
- post-operative radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Moderate-to-severe Atopic Dermatitis
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with…
- Trial name
- NCT06934252
- Testing
- TRB-061
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- TRex Bio, Inc.
Safety, Efficiency
To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis
Evaluate the safety and efficacy of Hemay5394 in patients with mild to moderate atopic dermatitis
- Trial name
- NCT07877155
- Testing
- Hemay5394 group, Control group
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Hemay Pharmaceutical PTY. LTD.